Tower Research Capital LLC TRC Acquires 11,377 Shares of Hologic, Inc. (NASDAQ:HOLX)

Tower Research Capital LLC TRC increased its holdings in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 214.9% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 16,671 shares of the medical equipment provider's stock after acquiring an additional 11,377 shares during the quarter. Tower Research Capital LLC TRC's holdings in Hologic were worth $1,202,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently bought and sold shares of the company. Barclays PLC lifted its stake in Hologic by 47.6% during the 3rd quarter. Barclays PLC now owns 718,231 shares of the medical equipment provider's stock valued at $58,507,000 after acquiring an additional 231,578 shares during the period. Wilmington Savings Fund Society FSB purchased a new position in shares of Hologic during the third quarter valued at approximately $93,000. Tidal Investments LLC lifted its position in Hologic by 60.1% during the third quarter. Tidal Investments LLC now owns 15,351 shares of the medical equipment provider's stock valued at $1,250,000 after purchasing an additional 5,764 shares during the period. Franklin Resources Inc. boosted its holdings in Hologic by 171.7% in the third quarter. Franklin Resources Inc. now owns 278,295 shares of the medical equipment provider's stock worth $22,714,000 after purchasing an additional 175,855 shares during the last quarter. Finally, Oddo BHF Asset Management Sas bought a new stake in Hologic in the 3rd quarter worth approximately $1,110,000. 94.73% of the stock is owned by hedge funds and other institutional investors.

Hologic Price Performance

Shares of Hologic stock traded up $0.06 on Monday, hitting $58.08. 1,579,266 shares of the company traded hands, compared to its average volume of 1,968,880. Hologic, Inc. has a 52 week low of $55.89 and a 52 week high of $84.67. The business has a 50-day simple moving average of $61.02 and a 200 day simple moving average of $69.93. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.78 and a current ratio of 3.49. The stock has a market capitalization of $13.03 billion, a P/E ratio of 18.32, a price-to-earnings-growth ratio of 2.14 and a beta of 0.82.

Hologic (NASDAQ:HOLX - Get Free Report) last announced its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. Research analysts expect that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the company. Royal Bank of Canada dropped their price target on Hologic from $88.00 to $85.00 and set a "sector perform" rating on the stock in a research note on Thursday, February 6th. Leerink Partners downgraded Hologic from an "outperform" rating to a "market perform" rating and cut their price target for the company from $80.00 to $75.00 in a research note on Thursday, February 6th. Morgan Stanley lowered their price objective on shares of Hologic from $84.00 to $82.00 and set an "equal weight" rating on the stock in a research note on Monday, January 13th. Raymond James restated an "outperform" rating and set a $90.00 target price (down from $95.00) on shares of Hologic in a research report on Thursday, February 6th. Finally, Leerink Partnrs downgraded shares of Hologic from a "strong-buy" rating to a "hold" rating in a research report on Thursday, February 6th. Eleven analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Hologic presently has an average rating of "Hold" and an average target price of $84.62.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.